publication venue for
- Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai 2007
- Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study. 27:e32-e55. 2020
- Stakeholders’ feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines. 27:e1-e24. 2020
- PRESCRIBING COMPETENCY OF MEDICAL STUDENTS: NATIONAL SURVEY OF MEDICAL EDUCATION LEADERS. 25:e18-e24. 2018
- A practical methodology for disaggregating the drivers of drug costs using administrative data. 24:16-24. 2017
- Increase in Psychoactive Drug Prescriptions in the Years Following Autism Spectrum Diagnosis: A Population-Based Cohort Study. 24:e19-e32. 2017
- Does the Number of Pharmacies a Patient Frequents Affect Adherence to Statins?. 24:e20-e50. 2017
- What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review. 24:e1-e20. 2017
- Assessing fasd in young children: Exploring clinical complexities and diagnostic challenges. 22:e108-e124. 2015
- Cost-sharing for health care services: An alternative strategy for pharmaceutical reimbursement in ontario. 22:e245-e250. 2015
- Development and Validation of the McMaster Prescribing Competency Assessment for Medical Trainees (MacPCA).. 22:e173-e178. 2015
- Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.. 22:e78-e89. 2015
- Evaluation of the neurobehavioral screening tool in children with fetal alcohol spectrum disorders (FASD).. 21:e197-e210. 2014
- Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.. 21:e357-e369. 2014
- Personalized benefit-harm information influences patient decisions regarding warfarin. 20. 2013
- Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.. 20:e229-e237. 2013
- The drug safety and effectiveness cross-disciplinary training (DSECT) program. 19:66-72. 2012
- A pilot study on cost-related medication nonadherence in Ontario.. 19:e239-e247. 2012
- Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.. 19:e166-e178. 2012
- Determing the threshold of acceptability of an ICER when natural health units are used.. 19:e234-e238. 2012
- Weighty matters: the association between mental health, pregnancy, and obesity.. 19:e483-e487. 2012
- Feeling different: the experience of living with fetal alcohol spectrum disorder.. 18:e475-e485. 2011
- A systematic review of medication safety outcomes related to drug interaction software.. 17:e243-e255. 2010
- An evaluation of pharmacist and health food store retailer's knowledge regarding potential drug interactions associated with St. John's wort.. 17:e57-e63. 2010
- An evaluation of pharmacist and health food store retailer's knowledge regarding potentional drug interactions associated with St. John's wort. 17. 2010
- Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.. 16:e273-e281. 2009
- Herbs, vitamins and minerals in the treatment of premenstrual syndrome: A systematic review. 16. 2009
- The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.. 16:e346-e359. 2009
- How complete are drug history profiles that are based on public drug benefit claims?. 15:e108-e116. 2008
- Medical residents' and students' attitudes towards herbal medicines: a pilot study.. 15:e1-e4. 2008
- Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).. 15:e177-e187. 2008
- Safety and efficacy of blue cohosh (Caulophyllum thalictroides) during pregnancy and lactation.. 15:e66-e73. 2008
- Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation.. 15:e74-e79. 2008
- Safety and efficacy of cranberry (vaccinium macrocarpon) during pregnancy and lactation.. 15:e80-e86. 2008
- Safety and efficacy of panax ginseng during pregnancy and lactation.. 15:e87-e94. 2008
- "I take what I think works for me": a qualitative study to explore patient perception of diabetes treatment benefits and risks.. 14:e251-e259. 2007
- A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.. 14:e215-e226. 2007
- A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.. 14:e215-e226. 2007
- Frequency of risk factors that potentially increase harm from medications in older adults receiving primary care.. 14:e283-e290. 2007
- Can contraindications compromise evidence-based, patient-centered clinical practice. 13:e92-101. 2006
- Natural health product use in Canada: analysis of the National Population Health Survey.. 13:e240-e250. 2006
- Safety and efficacy of St. John's wort (hypericum) during pregnancy and lactation.. 13:e268-e276. 2006
- Safety and efficacy of black cohosh (Cimicifuga racemosa) during pregnancy and lactation.. 13:e257-e261. 2006
- Safety and efficacy of echinacea (Echinacea angustafolia, e. purpurea and e. pallida) during pregnancy and lactation.. 13:e262-e267. 2006
- Safety and efficacy of ginkgo (Ginkgo biloba) during pregnancy and lactation.. 13:e277-e284. 2006
- Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.. 12:e229-e239. 2005
- Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.. 12:e254-e263. 2005
- A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada.. 11:e179-e190. 2004
- Placebos: our most effective therapy?. 11:e39-e40. 2004
- The economics of adjunctive therapies in coronary angioplasty: Drugs, devices or both?. 11. 2004
- An amantadine hydrochloride dosing program adjusted for renal function during an influenza outbreak in elderly institutionalized patients.. 10:119-122. 2003
- Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.. 10:67-71. 2003
- Renal impairment and medication use among psychogeriatric inpatients.. 10:78-82. 2003
- The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.. 10:17-23. 2003
- Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy.. 10:184-188. 2003
- An evaluation of the quality of herbal product information provided by health food store retailers and pharmacists in a Canadian city.. 9:108-109. 2002
- Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.. 9:79-99. 2002
- Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences.. 9:199-202. 2002
- Development of a standardized, comprehensive "ideal drug detail".. 8:73-77. 2001
- The place for prescribing guidelines and the means of their dissemination.. 8 Suppl A:29A-33A. 2001
- Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association.. 7:191-197. 2000
- The canadian society for clinical pharmacology in the post-royal college era.. 7:20-21. 2000
- Letter to the editor (multiple letters) [1]. 6:84. 1999
- Risk of drug dependence and abuse posed by barbiturate-containing analgesics.. 6:18-25. 1999
- Therapeutic equivalence: all studies are not created equal.. 6:9-11. 1999